Welcome to our dedicated page for Prophase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on Prophase Labs stock.
ProPhase Labs, Inc. (PRPH) generates a steady flow of company news across biotech, genomics, and consumer health. Its press releases and regulatory disclosures cover developments in molecular diagnostics, whole genome sequencing, OTC dietary supplements, capital markets activity, and strategic initiatives. For investors and followers of PRPH, this news stream provides insight into how the company is advancing its programs and managing its capital structure.
A major news theme for ProPhase is the BE-Smart Esophageal Cancer Test. Company announcements describe peer-reviewed validation studies conducted with Mayo Clinic, publication in leading gastroenterology journals, and plans for commercialization and clinical integration. Updates often detail BE-Smart’s performance metrics, its role in Barrett’s Esophagus risk stratification, and steps toward broader adoption and reimbursement discussions.
Another recurring topic is genomics and Nebula Genomics. ProPhase’s news highlights its whole genome sequencing offerings and the positioning of Nebula Genomics as a consumer genomics platform with a large and diverse DNA dataset. Releases also discuss related consumer health initiatives, including DNA Complete and DNA Expand product lines, within the company’s genomics and wellness strategy.
Capital structure and financing updates are also prominent in PRPH news. Recent items include information on senior secured convertible notes and warrants registered via an S-1, an at-the-market sales agreement, a 1-for-10 reverse stock split to address listing requirements, and shareholder communications about trading activity, convertible debt conversions, and the transition from Nasdaq to the OTC market. These disclosures explain how ProPhase is addressing liquidity, managing dilution, and aligning its share structure with strategic goals.
Strategic and legal developments appear as well, such as a non-binding Letter of Intent for a proposed reverse merger with Advanced Biological Laboratories S.A., the Crown Medical Collections receivables recovery initiative, and updates on legal matters disclosed in Form 8-K filings. For readers tracking PRPH, this news page aggregates these diverse updates in one place, making it easier to follow the company’s diagnostics, genomics, consumer health, and corporate actions over time.
ProPhase Labs, Inc. reported net sales of $3.6 million for Q2 2020, an increase from $1.7 million in Q2 2019. The company achieved net income of $70,000 ($0.01 per share), reversing a net loss of $1.2 million ($0.11 per share) year-over-year. For the first half of 2020, net sales totaled $5.5 million, up from $4.0 million in the prior year, with a reduced net loss of $0.7 million compared to $2.3 million. This improvement stemmed from a rise in third-party orders and reductions in costs across various expense categories.
ProPhase Labs, Inc. (NASDAQ: PRPH) reported Q1 2020 net sales of $1.9 million, down from $2.3 million in Q1 2019. The net loss narrowed to $809,000 or ($0.07) per share compared to a net loss of $1.0 million or ($0.09) per share the previous year. Contributing factors included a $430,000 decline in sales due to reduced customer demand, offset by decreased costs in administration ($206,000), marketing ($96,000), and R&D ($35,000). Additionally, the Company released $4.8 million from escrow following a resolved claim with Mylan on May 4, 2020.